Microbiota in cancer diagnosis, therapy and prevention

Background. An in-depth study of the participation of the microbiota in the pathogenesis of tumors has opened up new opportunities for the development of alternative approaches to the diagnosis, therapy and prevention of malignant neoplasms. Aim. To summarize the data on the practical use of microbiota profile features as a marker of carcinogenesis and diagnosis, as well as to consider its participation in the combined treatment and prevention of cancer. Materials and methods. A literature search was carried out in the databases NCBI MedLine (PubMed), Scopus, Web of Science using keywords that determine the purpose of the study. Results from original studies, meta-analyses, randomized controlled clinical trials, and traditional, systematic, and umbrella reviews published in recent years were analysed. Results. Qualitative and quantitative changes in the composition of the microbiota associated with the pathogenesis of oncological diseases make it possible to use them as markers for determining the risk of developing malignant neoplasms and predicting a wide range of tumors. The mechanisms that determine the use of the microbiota in anticancer therapy are diverse. The effect on the immune system is the most significant. Of great interest are artificially created hybrid nanoparticles covered with a membrane of bacterial vesicles and tumor cells to activate specific antitumor immunity. In terms of cancer prevention, the use of probiotics, prebiotics and synbiotics discovered by I. I. Mechnikov was fundamentally substantiated. Conclusion. The complex of scientific genomic and epigenetic data obtained in mechanistic and epidemiological studies on the role of the microbiota in the pathogenesis of tumors is currently evaluated as the most significant result justifying its practical application as a component of cancer diagnosis, therapy and prevention. © 2024, ABV-press Publishing House. All rights reserved.